Voronoi Inc
KOSDAQ:310210
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Voronoi Inc
Cash from Operating Activities
Voronoi Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Cash from Operating Activities
-₩29.1B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Cash from Operating Activities
₩646.1B
|
CAGR 3-Years
808%
|
CAGR 5-Years
13%
|
CAGR 10-Years
27%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Cash from Operating Activities
₩102.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Cash from Operating Activities
₩124.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
137%
|
CAGR 10-Years
49%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Cash from Operating Activities
-₩41.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Cash from Operating Activities
-₩21.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Voronoi Inc
Glance View
Voronoi, Inc. engages in the manufacture of novel kinase inhibitors and target protein degrader drugs. The company is headquartered in Incheon, Incheon. The company went IPO on 2022-06-24. The firm is principally engaged in the technology transfer of new drug candidates prior to electroclinical clinical trials. The firm is principally engaged in the research and development of kinase inhibitor as well as others. In addition, the Company is also engaged in the building and supply of new drug development platforms based on artificial intelligence (AI) and research results.
See Also
What is Voronoi Inc's Cash from Operating Activities?
Cash from Operating Activities
-29.1B
KRW
Based on the financial report for Dec 31, 2024, Voronoi Inc's Cash from Operating Activities amounts to -29.1B KRW.
What is Voronoi Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
3%
Over the last year, the Cash from Operating Activities growth was -1%. The average annual Cash from Operating Activities growth rates for Voronoi Inc have been -18% over the past three years , 3% over the past five years .
